Haemonetics Corporation
HAE
$57.17
$0.280.49%
NYSE
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.14% | 9.84% | 9.47% | 12.01% | 12.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.14% | 9.84% | 9.47% | 12.01% | 12.48% |
| Cost of Revenue | 4.45% | 5.76% | 6.08% | 9.41% | 12.87% |
| Gross Profit | 11.26% | 13.41% | 12.45% | 14.30% | 12.15% |
| SG&A Expenses | 2.44% | 5.55% | 11.04% | 12.09% | 7.62% |
| Depreciation & Amortization | 60.21% | 36.83% | 16.64% | -1.87% | -18.17% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.76% | 6.81% | 8.23% | 9.90% | 9.68% |
| Operating Income | 20.72% | 27.06% | 16.16% | 24.67% | 30.09% |
| Income Before Tax | 2.28% | -0.26% | -12.25% | 7.40% | 29.79% |
| Income Tax Expenses | 0.52% | 13.08% | 3.77% | 31.94% | 21.73% |
| Earnings from Continuing Operations | 2.76% | -3.48% | -15.87% | 1.87% | 32.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.76% | -3.48% | -15.87% | 1.87% | 32.18% |
| EBIT | 20.72% | 27.06% | 16.16% | 24.67% | 30.09% |
| EBITDA | 22.08% | 24.46% | 14.50% | 17.89% | 16.26% |
| EPS Basic | 2.55% | -4.07% | -16.21% | 1.99% | 32.86% |
| Normalized Basic EPS | 18.03% | 27.39% | 20.83% | 28.15% | 39.13% |
| EPS Diluted | 3.25% | -3.22% | -15.85% | 2.69% | 32.98% |
| Normalized Diluted EPS | 18.59% | 27.81% | 21.03% | 28.06% | 38.59% |
| Average Basic Shares Outstanding | 0.21% | 0.58% | 0.38% | -0.15% | -0.65% |
| Average Diluted Shares Outstanding | -0.27% | 0.24% | 0.23% | -0.04% | -0.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |